{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T11:05:23Z","timestamp":1784027123874,"version":"3.55.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T00:00:00Z","timestamp":1600214400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011676","name":"Elekta","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011676","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.radonc.2020.09.020","type":"journal-article","created":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T11:33:27Z","timestamp":1600256007000},"page":"243-248","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Dosimetric feasibility of hypofractionation for SBRT treatment of lymph node oligometastases on the 1.5T MR-linac"],"prefix":"10.1016","volume":"154","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1695-8515","authenticated-orcid":false,"given":"Dennis","family":"Winkel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4047-1520","authenticated-orcid":false,"given":"Anita M.","family":"Werensteijn-Honingh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wietse S.C.","family":"Eppinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn P.W.","family":"Intven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochem","family":"Hes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louk M.W.","family":"Snoeren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanne A.","family":"Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gijsbert H.","family":"Bol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas W.","family":"Raaymakers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina M.","family":"J\u00fcrgenliemk-Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6587-6204","authenticated-orcid":false,"given":"Petra S.","family":"Kroon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2020.09.020_b0005","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13014-017-0820-1","article-title":"Institutional analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lymph node metastases","volume":"12","author":"Yeung","year":"2017","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2020.09.020_b0010","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/s00066-017-1239-1","article-title":"Oligometastases in prostate cancer : Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT","volume":"194","author":"Baumann","year":"2018","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.radonc.2020.09.020_b0015","doi-asserted-by":"crossref","DOI":"10.1007\/s10585-018-9922-x","article-title":"Locoregional control and survival after lymph node SBRT in oligometastatic disease","author":"Loi","year":"2018","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.radonc.2020.09.020_b0020","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1118\/1.3438081","article-title":"Stereotactic body radiation therapy: the report of AAPM Task Group 101","volume":"37","author":"Benedict","year":"2010","journal-title":"Med Phys"},{"key":"10.1016\/j.radonc.2020.09.020_b0025","first-page":"5103","article-title":"Stereotactic body radiotherapy for recurrent or oligometastatic uterine cervix cancer: A cooperative study of the Korean radiation oncology group (KROG 14\u201311)","volume":"35","author":"Park","year":"2015","journal-title":"Anticancer Res"},{"key":"10.1016\/j.radonc.2020.09.020_b0030","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.euf.2017.07.006","article-title":"Exploring all avenues for radiotherapy in oligorecurrent prostate cancer disease limited to lymph nodes: A systematic review of the role of stereotactic body radiotherapy","volume":"3","author":"Ponti","year":"2017","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.radonc.2020.09.020_b0035","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s00345-014-1427-x","article-title":"Stereotactic radiotherapy for isolated nodal recurrence of prostate cancer","volume":"33","author":"Detti","year":"2015","journal-title":"World J Urol"},{"key":"10.1016\/j.radonc.2020.09.020_b0040","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.ijrobp.2016.01.032","article-title":"Stereotactic body radiation therapy for oligometastatic prostate cancer","volume":"95","author":"Muldermans","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.09.020_b0045","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13014-016-0586-x","article-title":"[(18)F]Choline PET\/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: preliminary results","volume":"11","author":"Pasqualetti","year":"2016","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2020.09.020_b0050","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00345-016-1860-0","article-title":"Stereotactic body radiotherapy in oligometastatic prostate cancer patients with isolated lymph nodes involvement: a two-institution experience","volume":"35","author":"Ingrosso","year":"2017","journal-title":"World J Urol"},{"key":"10.1016\/j.radonc.2020.09.020_b0055","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.ijrobp.2009.12.038","article-title":"Predictors of local control after single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases","volume":"79","author":"Greco","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.09.020_b0060","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1038\/bjc.2017.103","article-title":"Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study","volume":"116","author":"Triggiani","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.radonc.2020.09.020_b0065","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.3109\/0284186X.2015.1061693","article-title":"Impact of radiation dose and standardized uptake value of (18)FDG PET on nodal control in locally advanced cervical cancer","volume":"54","author":"Ramlov","year":"2015","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2020.09.020_b0070","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.eururo.2015.07.004","article-title":"Progression-free survival following stereotactic body radiotherapy for oligometastatic prostate cancer treatment-naive recurrence: a multi-institutional analysis","volume":"69","author":"Ost","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2020.09.020_b0075","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.eururo.2019.07.009","article-title":"Metastasis-directed therapy in treating nodal oligorecurrent prostate cancer: a multi-institutional analysis comparing the outcome and toxicity of stereotactic body radiotherapy and elective nodal radiotherapy","volume":"76","author":"De Bleser","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2020.09.020_b0080","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/COC.0b013e31818da9f7","article-title":"Economic analysis of radiation therapy oncology group 97\u201314: multiple versus single fraction radiation treatment of patients with bone metastases","volume":"32","author":"Konski","year":"2009","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.radonc.2020.09.020_b0085","doi-asserted-by":"crossref","first-page":"7233","DOI":"10.1088\/1361-6560\/aa82ae","article-title":"Towards fast online intrafraction replanning for free-breathing stereotactic body radiation therapy with the MR-linac","volume":"62","author":"Kontaxis","year":"2017","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.radonc.2020.09.020_b0090","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3857\/roj.2015.33.4.265","article-title":"Radiobiological mechanisms of stereotactic body radiation therapy and stereotactic radiation surgery","volume":"33","author":"Kim","year":"2015","journal-title":"Radiat Oncol J"},{"key":"10.1016\/j.radonc.2020.09.020_b0095","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ijrobp.2013.07.022","article-title":"The tumor radiobiology of SRS and SBRT: are more than the 5 Rs involved?","volume":"88","author":"Brown","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.09.020_b0100","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.ijrobp.2016.08.036","article-title":"Simulated online adaptive magnetic resonance-guided stereotactic body radiation therapy for the treatment of oligometastatic disease of the abdomen and central thorax: characterization of potential advantages","volume":"96","author":"Henke","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.09.020_b0105","article-title":"Simulated dosimetric impact of online replanning for stereotactic body radiation therapy of lymph node oligometastases on the 1.5T MR-linac","volume":"1\u20138","author":"Winkel","year":"2018","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2020.09.020_b0110","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.radonc.2017.11.032","article-title":"Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen","volume":"126","author":"Henke","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.09.020_b0115","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.semradonc.2014.02.008","article-title":"The ViewRay system: magnetic resonance-guided and controlled radiotherapy","volume":"24","author":"Mutic","year":"2014","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.radonc.2020.09.020_b0120","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.ijrobp.2015.10.015","article-title":"Online magnetic resonance image guided adaptive radiation therapy: first clinical applications","volume":"94","author":"Acharya","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.09.020_b0125","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.radonc.2017.07.028","article-title":"Fast and robust online adaptive planning in stereotactic MR-guided adaptive radiation therapy (SMART) for pancreatic cancer","volume":"125","author":"Bohoudi","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.09.020_b0130","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.radonc.2007.10.034","article-title":"MRI\/linac integration","volume":"86","author":"Lagendijk","year":"2008","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.09.020_b0135","doi-asserted-by":"crossref","first-page":"L41","DOI":"10.1088\/1361-6560\/aa9517","article-title":"First patients treated with a 1.5 T MRI-Linac: clinical proof of concept of a high-precision, high-field MRI guided radiotherapy treatment","volume":"62","author":"Raaymakers","year":"2017","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.radonc.2020.09.020_b0140","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.radonc.2019.01.024","article-title":"Feasibility of stereotactic radiotherapy using a 1.5 T MR-linac: Multi-fraction treatment of pelvic lymph node oligometastases","volume":"134","author":"Werensteijn-Honingh","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.09.020_b0145","article-title":"Adaptive radiotherapy: The Elekta Unity MR-linac concept","author":"Winkel","year":"2019","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.radonc.2020.09.020_b0150","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.3109\/0284186X.2015.1062541","article-title":"Comparison of onboard low-field magnetic resonance imaging versus onboard computed tomography for anatomy visualization in radiotherapy","volume":"54","author":"Noel","year":"2015","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2020.09.020_b0155","article-title":"Individual lymph nodes: \u201cSee it and Zap it\u201d","author":"Winkel","year":"2019","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.radonc.2020.09.020_b0160","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3389\/fonc.2017.00059","article-title":"R-IDEAL: A framework for systematic clinical evaluation of technical innovations in radiation oncology","volume":"7","author":"Verkooijen","year":"2017","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2020.09.020_b0165","doi-asserted-by":"crossref","first-page":"e291","DOI":"10.1016\/j.prro.2016.05.004","article-title":"Rationale of technical requirements for NRG-BR001: The first NCI-sponsored trial of SBRT for the treatment of multiple metastases","volume":"6","author":"Al-Hallaq","year":"2016","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.radonc.2020.09.020_b0170","unstructured":"Chmura S, Salama JK, Robinson C, Pisansky TM, Borges V, Al-Hallaq HA, et al. A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases. ClinicalTrials.gov NCT022063342015."},{"key":"10.1016\/j.radonc.2020.09.020_b0175","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.radonc.2014.05.013","article-title":"Position shifts and volume changes of pelvic and para-aortic nodes during IMRT for patients with cervical cancer","volume":"111","author":"Schippers","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.09.020_b0180","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.radonc.2020.02.011","article-title":"Target coverage and dose criteria based evaluation of the first clinical 1.5T MR-linac SBRT treatments of lymph node oligometastases compared with conventional CBCT-linac treatment","volume":"146","author":"Winkel","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.09.020_b0185","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.ijrobp.2010.11.031","article-title":"Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer","volume":"82","author":"Jereczek-Fossa","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.09.020_b0190","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4103\/0971-6203.62194","article-title":"CyberKnife: A new paradigm in radiotherapy","volume":"35","author":"Kurup","year":"2010","journal-title":"J Med Phys"},{"key":"10.1016\/j.radonc.2020.09.020_b0195","doi-asserted-by":"crossref","first-page":"S1006","DOI":"10.1016\/S0167-8140(17)32273-9","article-title":"EP-1838: First IGRT results for SBRT bone and lymph node oligometastases within the pelvic region","volume":"123","author":"Wiersema","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.09.020_b0200","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.phro.2017.02.003","article-title":"Pancreatic tumor motion reduction by use of a custom abdominal corset","volume":"2","author":"Heerkens","year":"2017","journal-title":"Phys Imag Radiat Oncol"},{"key":"10.1016\/j.radonc.2020.09.020_b0205","doi-asserted-by":"crossref","first-page":"7407","DOI":"10.1088\/1361-6560\/aa83f7","article-title":"Effect of intra-fraction motion on the accumulated dose for free-breathing MR-guided stereotactic body radiation therapy of renal-cell carcinoma","volume":"62","author":"Stemkens","year":"2017","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.radonc.2020.09.020_b0210","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ijrobp.2016.09.030","article-title":"Benchmark credentialing results for NRG-BR001: The first national cancer institute-sponsored trial of stereotactic body radiation therapy for multiple metastases","volume":"97","author":"Al-Hallaq","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.09.020_b0215","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1120\/jacmp.v12i2.3368","article-title":"Dose tolerance limits and dose volume histogram evaluation for stereotactic body radiotherapy","volume":"12","author":"Grimm","year":"2011","journal-title":"J Appl Clin Med Phys"},{"key":"10.1016\/j.radonc.2020.09.020_b0220","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1177\/1533034617741797","article-title":"Focal MRI-guided salvage high-dose-rate brachytherapy in patients with radiorecurrent prostate cancer","volume":"16","author":"Maenhout","year":"2017","journal-title":"Technol Cancer Res Treat"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814020307933?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814020307933?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:15:17Z","timestamp":1759122917000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814020307933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":44,"alternative-id":["S0167814020307933"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2020.09.020","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dosimetric feasibility of hypofractionation for SBRT treatment of lymph node oligometastases on the 1.5T MR-linac","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2020.09.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}